Investment Thesis
Allarity Therapeutics is a pre-revenue pharmaceutical company with substantial operating losses and negative cash flow, burning approximately $11.6M annually with only $16.9M in cash reserves. The company faces critical existential risk as it will deplete its cash runway within 18 months at current burn rates, with no clear path to profitability or positive cash generation.
ALLR Strengths
- Strong liquidity position with $16.9M in cash and 2.33x current ratio providing near-term operational runway
- Conservative leverage with 0.22x debt-to-equity ratio limiting financial distress risk
- Pharmaceutical sector offers high-growth potential if development programs achieve clinical success
ALLR Risks
- Severe cash burn of $11.9M annual free cash flow will exhaust reserves within approximately 18 months without revenue generation or additional financing
- Negative revenue of $1.3M indicates cost structure issues and no commercial traction despite sector presence
- Operating losses of $9.7M and net losses of $7.9M with deteriorating financial position typical of failed clinical-stage biotech programs
Key Metrics to Watch
- Cash runway depletion timeline and need for dilutive financing
- Revenue trajectory and timing of first commercial product approval
- Monthly operating cash burn rate and runway extension initiatives
ALLR Financial Metrics
ALLR Profitability Ratios
ALLR Balance Sheet & Liquidity
ALLR 5-Year Financial Trend
5-Year Trend Summary: Allarity Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3,093.42 indicates the company is currently unprofitable.
ALLR Growth Metrics (YoY)
ALLR Capital Allocation
ALLR SEC Filings
Access official SEC EDGAR filings for Allarity Therapeutics, Inc. (CIK: 0001860657)